AHA Scientific Sessions 2026 Abstract · Nov 2, 2026
Residual Inflammatory Risk in Statin-Treated U.S. Adults with LDL Cholesterol < 70 mg/dL: The Role of Metabolic Syndrome and Central Obesity
By Ndulue J
Background: Residual inflammatory risk (RIR), commonly defined as elevated high-sensitivity C-reactive protein (hsCRP) levels despite statin therapy, contributes to persistent cardiovascular risk beyond lipid-lowering effects. However, determinants of RIR among statin-treated individuals who have already achieved optimal low-density lipoprotein cholesterol (LDL-C) control remain incompletely characterized. This study evaluated the prevalence and predictors of RIR among statin-treated U.S. adults with LDL-C <70 mg/dL. Methods: Statin-treated adults with LDL-C <70 mg/dL were identified from the National Health and Nutrition Examination Survey (NHANES) 2015-2016 and 2017-2020 pre-pandemic cycles. LDL-C was calculated using the NIH equation. RIR was defined as hsCRP ≥2 mg/L. Survey-weighted analyses incorporating fasting subsample weights were performed. Baseline characteristics were compared according to RIR status. Multivariable survey logistic regression was used to identify independent predictors of RIR. Results: Among statin-treated adults with LDL-C <70 mg/dL (weighted population estimate: 10.8 million U.S. adults), 43.3% exhibited RIR despite achieving contemporary LDL-C treatment targets. Participants with metabolic syndrome demonstrated a significantly greater prevalence of RIR compared with those without metabolic syndrome (55.1% vs. 29.4%, p=0.004). In multivariable analysis, metabolic syndrome was independently associated with RIR (adjusted OR 3.52, 95% CI 1.57-7.88, p=0.003). Current smoking (adjusted OR 2.72, 95% CI 1.04-7.14, p=0.042), presence of 1-2 comorbidities (adjusted OR 2.47, 95% CI 1.18-5.19, p=0.018), and younger age (adjusted OR per year 0.96, 95% CI 0.93-0.99, p=0.009) were independently associated with RIR. HOMA-IR, sex, and attainment of physical activity guidelines were not independently associated with RIR. In a sensitivity analysis, waist circumference remained independently associated with RIR (adjusted OR 1.04 per cm, 95% CI 1.01-1.07, p=0.010). Conclusions: Nearly half of statin-treated U.S. adults with LDL-C <70 mg/dL had residual inflammatory risk despite reaching guideline-recommended lipid targets. Metabolic syndrome was the strongest independent predictor of RIR and was associated with more than threefold higher odds of persistent inflammation. Current smoking and younger age were also independently associated with RIR, and greater waist circumference remained significant in sensitivity analyses. These findings suggest that meeting LDL-C targets alone may not fully reduce residual cardiovascular risk and identify metabolic dysfunction and central obesity as potential targets for lowering persistent inflammation in statin-treated patients.